ArtPark Moving Studios — a local nonprofit that provides art programming for at-risk children — took home a big prize at last year's Project Flourish. Courtesy of First Presbyterian Church

First Presbyterian Church of Houston launched the second round of Project Flourish, a social entrepreneurship contest, on August 18.

The contest is "a creative invitation to the community to help bring fresh ideas to the issues that face a major metropolitan city like Houston," reads a news release. The pitch competition is open to for-profit or nonprofit ideas. What's on the line? Up to $250,000 in seed money, to be divided among an undetermined number of winners as the judges see fit.

Although the church has held the competition in the past, it has made some changes to the newest iteration of the program. Past applicants were not required to have a Houston focus, but this year's individuals and teams must live within 50 miles of downtown Houston and their idea must impact Houston. Those who make it to the semi-final round will be invited to join the eight-week accelerator program, in which they will receive consulting and mentoring in preparation for pitching their ideas to the judges.

Austin Hermann, FPC's Director of the Center for Faith, Work, and Innovation, oversees Project Flourish. When InnovationMap asked him why the contest matters for Houston, Hermann says it's about lending a helping hand to Houston entrepreneurs.

"When you look at all the different groups that are trying to start things in Houston, there's a major gap in the ecosystem… Project Flourish is trying to fill that gap," he says. "We want to connect Houston-based and Houston-focused entrepreneurs who are in the earliest stages of idea formation to the resources of a church — social, intellectual, and financial capital — in a way that other institutions don't because they're not interested in small deals. [We offer] impact investing for and towards groups of individuals who can't get that access anywhere else."

According to a release, in Project Flourish's inaugural round, which concluded in March 2018, funding recipients included art studio on wheels nonprofit ArtPark Moving Studios, which won $55,000, and Rescue Houston, which claimed a $45,000 prize and focuses on empowering victims of sex trafficking.

Hermann says he's most excited about the new Houston emphasis this year as well as the opportunity to get new people involved. The program process is largely the same, but allows a new set of entrepreneurs, application screeners, navigators, skills coaches, and judges to take part.

"We're putting a call out for new ventures [that are] seeking the good of Houston."

For more information or to apply, please visit projectflourish.org. The application is live now through November 1.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”